RecruitingNot ApplicableNCT06163781

Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning

Appropriate Use of Blood Cultures in the Emergency Department Through Machine Learning: a Randomized Controlled Trial


Sponsor

Amsterdam UMC, location VUmc

Enrollment

7,584 participants

Start Date

Feb 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to study whether the use of our blood culture prediction tool is non-inferior to current practice and if it can improve certain outcomes in all adult patients presenting to the emergency department with a clinical indication for a blood culture analysis (according to the treating physician). The primary endpoint is 30-day mortality. Key secondary outcomes are: * hospital admission rates * in-hospital mortality * hospital length-of-stay. In the intervention group, the physician will follow the advice of our blood culture prediction tool. In the comparison group all patients will undergo a blood culture analysis.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age \>= 18 years
  • Have a clinical indication for a blood culture analysis (according to the treating physician)
  • Have sufficient data recorded (laboratory results and vital sign measurements) for a prediction to be made (at least 20% of the needed parameters)

Exclusion Criteria6

  • Central Venous Line (CVL) or Peripherally Inserted Central Catheter (PICC) in situ
  • Neutrophil count \< 0.5 \* 109/L
  • Candidemia or S. aureus bacteraemia in the past 3 months.
  • Most likely diagnosis of endocarditis/spondylodiscitis/infected prosthetic material
  • Pregnant or breastfeeding patients
  • Not capable of giving informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBlood culture prediction tool

Machine learning based predicition tool


Locations(1)

Amsterdam UMC - location AMC

Amsterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06163781


Related Trials